Through its new partnership withAntibodies Incorporated, Aves now offers highly-cited primary antibodies from Neuromab.
In response to the growing epidemic of poorly characterized antibodies, the NIH set out in 2005 to create a collection of painstakingly-validated antibodies for the neuroscience community. These antibodies were developed by the NIH-funded, UC Davis-based NeuroMab facility, and Antibodies Incorporated was selected as the production and distribution partner for the initiative. Since its inception in 2005, the project has yielded nearly 500 antibodies, many of them knockout-validated on mouse brain.
Most NeuroMab antibodies are sold either in TC Supernatant or Purified forms:
TC Supernatant Hybridoma tissue-culture supernatant (5mL) generally containing 10-50 ug/mL monoclonal antibody (clone-dependent) can be a very economical choice. Supernatant is suitable for most applications including Western Blot, immunocytochemistry, immunohistochemistry, etc. For applications requiring higher antibody concentration or purity (such as immunoprecipitation, microinjection, or conjugation) it is recommended that you purchase the purified form.
Purified Produced by in vitro bioreactor culture of hybridoma lines followed by Protein A affinity chromatography. Purified mAbs are >90% specific antibody at 1mg/mL.